Etanercept: An overview

被引：149

作者：

Goffe, B

Cather, JC

机构：

[1] Univ Washington, Dept Dermatol, Seattle, WA 98104 USA

[2] Texas Dermatol Associates, Dallas, TX USA

[3] Baylor Univ, Med Ctr, Dallas, TX USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2003年 / 49卷 / 02期

关键词：

D O I：

10.1016/mjd.2003.554

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

引用

页码：S105 / S111

页数：7

共 29 条

[11]

GOTTLIEB AB, 2002, ANN DERMATOL VENER, V129, pS280

[12]

*IMM CORP WYETH AY, 2002, ET PACK INS

[13] Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].